Eur Respir J 2004; 23:671-678
Copyright ©ERS Journals Ltd 2004
Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro
K. Kanai1,
K. Asano2,
T. Hisamitsu2 and
H. Suzaki1
1 Dept of Otolaryngology, and 2 Dept of Physiology, School of Medicine, Showa University, Tokyo, Japan
CORRESPONDENCE: K. Asano, Dept of Physiology, School of Medicine, Showa University, 1-5-8 Hatanodai Shinagawa-ku, Tokyo 142-8555, Japan. Fax: 81 337845368. E-mail: asanok@med.showa-u.ac.jp
Keywords: Fibroblast, in vitro, macrolide antibiotic, matrix metalloproteinase, suppression
Received: May 23, 2003
Accepted December 18, 2003
It is well known that low-dose and long-term administration of macrolide antibiotics favourably modify the clinical status of chronic airway inflammatory diseases. However, the therapeutic mode of action of macrolide antibiotics is not well understood. The present study aimed to examine the influence of macrolide antibiotics, roxithromycin (RXM) and josamycin (JM) on matrix metalloproteinase (MMP) production from nasal polyp fibroblasts (NPF) in vitro.
NPF, at a concentration of 2.5x105 cells·mL1, were stimulated with tumour necrosis factor (TNF)- in the presence of various concentrations of RXM or JM for 24 h. MMP-2 and -9 levels in culture supernatants were analysed by ELISA, and MMP mRNA expression was examined by RT-PCR. The influence of RXM on nuclear factor (NF)- B and activator protein (AP)-1 activation was also examined.
Addition of RXM (but not JM) at 5.0 and 7.5 µg·mL1 significantly suppressed the production of MMP-2 and -9 from NPF induced by TNF- stimulation. RXM also suppressed MMP mRNA expression through the inhibition of NF- B and AP-1 activation.
The present results suggest that the suppressive activity of roxithromycin on MMP-2 and -9 production is, in part, responsible for the therapeutic action of macrolides on chronic airway inflammatory diseases.
This article has been cited by other articles:

|
 |

|
 |
 
M. Ogawa, J.-i. Suzuki, K. Hishikari, K. Takayama, H. Tanaka, and M. Isobe
Clarithromycin Attenuates Acute and Chronic Rejection Via Matrix Metalloproteinase Suppression in Murine Cardiac Transplantation
J. Am. Coll. Cardiol.,
May 20, 2008;
51(20):
1977 - 1985.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yasuda, K. Kasahara, F. Mizuno, K. Nishi, K. Mikasa, and E. Kita
Roxithromycin Favorably Modifies the Initial Phase of Resistance against Infection with Macrolide-Resistant Streptococcus pneumoniae in a Murine Pneumonia Model
Antimicrob. Agents Chemother.,
May 1, 2007;
51(5):
1741 - 1752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Lotter, K. Hocherl, M. Bucher, and F. Kees
In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice
J. Antimicrob. Chemother.,
September 1, 2006;
58(3):
615 - 621.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Yates, D. M. Murphy, I. A. Forrest, C. Ward, R. M. Rutherford, A. J. Fisher, J. L. Lordan, J. H. Dark, and P. A. Corris
Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome
Am. J. Respir. Crit. Care Med.,
September 15, 2005;
172(6):
772 - 775.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barnes and R. A. Stockley
COPD: current therapeutic interventions and future approaches
Eur. Respir. J.,
June 1, 2005;
25(6):
1084 - 1106.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the European Respiratory Society.
|